Nanoparticle‐conjugated PSs can exploit tumor‐specific cell surface receptors, delivering the PS directly to tumor cells and reducing off‐target effects.[132] This development not only increases the precision of PDT but also minimizes the potential for skin photosensitivity and other side effects associated with PS activation. Here, CD177 is linked to neoplasm.